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Background: Preclinical studies suggest that interleukin-9 may be a central mediator in the development and
maintenance of airway inflammation in asthma. The aim of this study was therefore to evaluate the effects of MEDI-528,
an anti-interleukin-9 monoclonal antibody, in adults with confirmed uncontrolled moderate-to-severe asthma.
Methods: In this prospective double-blind, multicenter, parallel-group study, 329 subjects were randomized
(1:1:1:1) to subcutaneous placebo or MEDI-528 (30, 100, 300 mg) every 2 weeks for 24 weeks, in addition to their
usual asthma medications. The primary endpoint was change in mean Asthma Control Questionnaire-6 (ACQ-6)
score at week 13. Secondary endpoints included weighted asthma exacerbation rates and pre-bronchodilator
forced expiratory volume in 1 second (FEV1) at weeks 13 and 25, as well as Asthma Quality of Life Questionnaire
scores at weeks 12 and 25 and the safety of MEDI-528 throughout the study period. The primary endpoint was
analyzed using analysis of covariance.
Results: The study population (n = 327) was predominantly female (69%) with a mean age of 43 years (range 18–65).
The mean (SD) baseline ACQ-6 score for placebo (n = 82) and combined MEDI-528 (n = 245) was 2.8 (0.7) and 2.8 (0.8);
FEV1 % predicted was 70.7% (15.9) and 71.5% (16.7). Mean (SD) change from baseline to week 13 in ACQ-6 scores for
placebo vs combined MEDI-528 groups was −1.2 (1.0) vs −1.2 (1.1) (p = 0.86). Asthma exacerbation rates (95% CI) at
week 25 for placebo vs MEDI-528 were 0.58 (0.36–0.88) vs 0.49 (0.37–0.64) exacerbations/subject/year (p = 0.52). No
significant improvements in FEV1 % predicted were observed between the placebo and MEDI-528 groups. Adverse
events were comparable for placebo (82.9%) and MEDI-528 groups (30 mg, 76.5%; 100 mg, 81.9%; 300 mg, 85.2%).
The most frequent were asthma (placebo vs MEDI-528, 30.5% vs 33.5%), upper respiratory tract infection (14.6% vs
17.1%), and headache (9.8% vs 9.8%).
Conclusions: The addition of MEDI-528 to existing asthma controller medications was not associated with any
improvement in ACQ-6 scores, asthma exacerbation rates, or FEV1 values, nor was it associated with any major
safety concerns.
Trial registration: ClinicalTrials.gov: NCT00968669.
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Asthma is a chronic inflammatory airway disease charac-
terized by variable airflow limitation, airway hyperrespon-
siveness, mucus hypersecretion, and structural changes to
the airways that include proliferation of smooth muscle
[1]. Interleukin (IL)-9, a multifunctional cytokine produced* Correspondence: hultquistm@medimmune.com
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reproduction in any medium, provided the orby type 2 T helper cells (Th2), lymphocytes, and mast
cells, is proposed to be a central mediator in the patho-
genesis of asthma. Interest in IL-9 was first triggered by
genetic linkage studies [2] and supported by the finding
that expression of IL-9 and its associated receptor is
higher in the airways of subjects with asthma compared
with healthy controls [3,4]. Further evidence has come
from in vitro studies showing that IL-9 enhances the
growth and/or activity of a variety of cell types and pro-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cated in the pathogenesis of asthma [5]. IL-9 induced the
release of Th2-associated chemokines in cultured human
airway smooth muscle cells [6] and enhanced the stem cell
factor-dependent growth of human mast cell progenitors,
particularly those from children with asthma [7]. Another
study reported that IL-9 upregulated mucin expression
in human lung cells, suggesting that it is involved in the
control of mucus secretion [8].
Preclinical studies in animal models of asthma support
a contributing role for an IL-9 mast cell axis in the
immunopathology of asthma [5]. In one study, anti-IL-
9 antibody treatment had a protective effect against airway
remodeling in mouse models of airway inflammation,
together with a concomitant reduction in the number
and activation of mature mast cells [9]. Furthermore,
impaired lung function related to airway remodeling was
reversed by IL-9 neutralization. Taken together, evidence
from these and other experimental studies indicated that
targeting IL-9 may offer a novel approach to the treatment
of asthma.
MEDI-528 is a humanized immunoglobulin G1 mono-
clonal antibody that binds to IL-9 [10], and hence reduces
the activity of a variety of cell types implicated in asthma
pathogenesis [5]. Preliminary clinical studies in healthy
adults and subjects with mild or mild-to-moderate asthma
have demonstrated that MEDI-528 administered subcuta-
neously has linear pharmacokinetics and an acceptable
safety profile with no reports of serious adverse events
(SAEs) [11,12]. One study in subjects with mild asthma
showed that MEDI-528 had no effect on pulmonary
function or the use of rescue medication, although there
were positive trends for improvement in asthma symptom
scores and for a reduction in the number of asthma
exacerbations [11]. Another study in a small number of
subjects with mild-to-moderate asthma suggested that
MEDI-528 may decrease sensitivity to exercise-induced
bronchoconstriction that is dependent on mast cell
degranulation [11]. We now report the results from a
larger study (ClinicalTrials.gov, NCT00968669) that was
designed to further investigate the potential clinical
benefits of MEDI-528 in treating subjects with asthma.
The primary objective of this study was to evaluate the
effect of multiple dose subcutaneous administration of
MEDI-528 on symptom control in adults with uncon-
trolled, moderate-to-severe, persistent asthma.
Methods
Subjects
Eligible subjects were aged 18–65 years with body mass
index 18–35 kg/m2 and a clinical diagnosis of asthma,
confirmed by pre-bronchodilator forced expiratory volume
in 1 second (FEV1) ≥ 40% predicted and post-bronchodila-
tor FEV1 reversibility ≥ 12% and ≥ 200 mL.Subjects were required to have poor asthma symptom
control [1], as demonstrated by an Asthma Control
Questionnaire-6 (ACQ-6) score ≥ 1.5 [13], daytime
symptoms on ≥ 2 days/week, night-time awakening ≥ 1
night/week, rescue medication use on ≥ 2 days/week,
and ≥ 1 asthma exacerbation in the past year. Subjects
were either currently taking medium to high-dose
inhaled corticosteroids (ICS) or were eligible to take
them based on Expert Panel Report 3 guidelines, and
were started on medium to high-dose ICS at the start of
the run-in phase of the study [1]. Key exclusion criteria
were the presence of other lung diseases, severe depres-
sion or history of suicidal behavior, tobacco smoking (≥
10 pack-years), recent illness or infection, or clinically
significant electrocardiogram (ECG) abnormalities. Treat-
ment with any other biologic agent or immunosuppressive
medication (apart from ≤ 10 mg/day oral prednisone or
equivalent, or inhaled or topical corticosteroids) was not
allowed during the month prior to and throughout the
study. Subjects were permitted to receive a short burst
of systemic corticosteroid therapy or be hospitalized to
control an asthma exacerbation.
All subjects provided written informed consent before
participating in the study. The protocol was approved by
an Independent Ethics Committee at each study center,
and the study was conducted in accordance with Inter-
national Conference on Harmonisation Guidance for Good
Clinical Practice and the Declaration of Helsinki.
Study design and randomization
This phase 2b, randomized, double-blind, placebo-con-
trolled, parallel group study was conducted at 53 sites
in North America, Central America, South America, and
Asia between October 2009 and November 2011. The
study consisted of a 4-week screening period, a 13-week
steroid stable treatment period, an 11-week steroid re-
duction treatment period, and a 22-week follow-up period
(Figure 1). The ICS dosage was optimized and stabilized
during the screening period, maintained unchanged
throughout the steroid-stable treatment period, and
was reduced in subjects with clinically stable asthma
during the steroid-reduction treatment period. Subjects
were seen at the clinic twice during the screening period
(weeks −4 and −2), at two-weekly intervals during the
treatment period (weeks 0 to 24) with an additional
visit at week 13, and then at four-weekly intervals during
the post-treatment follow-up period (weeks 25 to 46).
Subjects were randomized (1:1:1:1) using an interactive
voice response system to receive placebo or one of three
doses of MEDI-528 (30, 100, or 300 mg) subcutaneously
every 2 weeks for 24 weeks (13 doses), in addition to
their usual asthma medications. Because MEDI-528 and
placebo are visually distinct, study medication was admin-
istered at the clinic by unblinded personnel who were
30 mg s.c. every 2 weeks (n = 80)
-4 0 13 4625
MEDI-528
100 mg s.c. every 2 weeks (n = 80)MEDI-528
300 mg s.c. every 2 weeks (n = 80)MEDI-528
s.c. every 2 weeks (n = 80)Placebo













Figure 1 Study design. aInhaled corticosteroids at stable dose: fluticasone/salmeterol (500 μg/50 μg or 250 μg/50 μg) or budesonide/formoterol
(160 μg/4.5 μg). bSubjects with clinically stable asthma could reduce their inhaled corticosteroid dose to: fluticasone/salmeterol (250 μg/50 μg or
100 μg/50 μg) or budesonide/formoterol (80 μg/4.5 μg). Abbreviations: ACQ-6, Asthma Control Questionnaire-6; FEV1, Forced expiratory volume in
1 second; s.c, Subcutaneous.
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blinding.
Randomization was stratified by asthma status (atopic
or non-atopic) and ICS dose (medium or high). High-dose
ICS was defined as 1 puff twice a day of fluticasone/
salmeterol (500 μg/50 μg) and medium dose ICS was
defined as 1 puff twice a day fluticasone/sal meterol
(250 μg/50 μg) or 2 puffs twice a day budesonide/
formoterol (160 μg/4.5 μg). Only subjects who were
taking medium- to high-dose ICS at screening were en-
rolled. Subjects who were uncontrolled while receiving
medium-dose ICS were enrolled to the medium-dose or
high-dose ICS group at the study physician’s discretion
depending on their level of asthma control, and subjects
receiving high-dose ICS were enrolled to the high-ICS
group. Randomization of subjects with non-atopic asthma
was restricted to ensure that a minimum of 160 subjects
with atopic asthma were included in the study.
Primary and secondary outcomes
The primary efficacy outcome was change from baseline
in mean ACQ-6 score at week 13 among individual
MEDI-528 treatment groups and placebo. Secondary
outcomes included change from baseline in mean ACQ-6
score at week 25, asthma exacerbation rates (week 25),
pre-bronchodilator FEV1 (weeks 13 and 25), health-related
quality of life (Asthma Quality of Life Questionnaire
(Standardized version) [AQLQ(S)] scores; weeks 12 and




The ACQ-6 was completed at home on a weekly basis,
using an electronic patient-reported outcome device.
The occurrence of any asthma exacerbations during the
study was recorded by the study physician at each clinic
visit. Asthma exacerbation was defined as a progressiveincrease in asthma symptoms (cough, wheeze, chest tight-
ness, and/or shortness of breath) with a reduction from
baseline or best previous measurement of ≥ 20% in FEV1
or peak expiratory flow (PEF) rate that did not resolve
after the initiation of rescue medication and resulted in
a prescription for, or administration of, systemic cortico-
steroid burst therapy. An exacerbation was considered
to be resolved when the subject’s asthma symptoms
had diminished, and PEF or FEV1 returned to > 80% of
baseline for ≥ 7 days after completion of systemic cortico-
steroid burst therapy. Pre-bronchodilator spirometry was
conducted according to the American Thoracic Society/
European Respiratory Society guidelines [14]. All spirom-
etry assessments for each subject were performed at
the same time of day (± 1 hour) and in the same manner.
Between three and eight forced expiratory efforts were
made at each session and the maximum FEV1 of the two
best efforts was recorded.Health-related quality of life
The AQLQ(S) was completed every 4 weeks at home
using the electronic patient-reported outcome device.Safety profile
Details of any adverse events (AEs) and SAEs were re-
corded. AEs were defined as any untoward medical occur-
rence that occurred after initiation of study medication.
Blood and urine samples were collected at screening, prior
to the first dose, at 4-weekly intervals during the treatment
period, and 8-weekly intervals during the follow-up period
for routine clinical laboratory evaluations. Vital signs
(blood pressure, heart rate, temperature, and respiratory
rate) were monitored at every clinic visit. A computerized
12-lead ECG was recorded. Blood samples were collected
for determination of the presence of anti-drug antibodies
(ADAs) using an enzyme-linked immunosorbent or elec-
trochemiluminescent assay [12].
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Sample size calculations were based on an assumed change
from baseline to week 13 in mean ACQ-6 score of −0.4
to −0.5 for placebo and −0.9 to −1.1 for the MEDI-528
groups, with a common standard deviation (SD) of 0.8 to
1.0 [15,16]. Sixty subjects in each treatment group would
allow detection of a statistically significant difference
between treatment groups with 58–99% power based
on a 2-sided type I error of 0.05 and 0.10. Assuming a
drop-out rate of 20%, it was planned to randomize 80
subjects into each treatment group.
The intent-to-treat (ITT) population was defined as
all randomized subjects who received either placebo or
MEDI-528. The safety population included all subjects
who received either placebo or MEDI-528 and had safety
data. Statistical analysis of clinical activity was based on
a comparison of placebo with the individual MEDI-528
treatment groups for the ITT population.
Change from baseline (week 0) in mean ACQ-6 score
at weeks 13 (primary endpoint) and 25 was analyzed using
an analysis of covariance model. The model included
the treatment group, atopic asthma status, geographic
region, baseline eosinophil level, and mean ACQ score
at baseline. Any missing ACQ-6 scores at weeks 13 and
25 were imputed using the last observation carried for-
ward method. A sensitivity analysis was performed after
excluding subjects with missing ACQ-6 scores at weeks
13 and 25. The proportion of subjects with an improve-
ment in mean ACQ-6 score of ≥ 0.5 at weeks 13 and 25
was compared between placebo and MEDI-528 using
Fisher’s exact test. Subgroup analyses were conducted on
the primary efficacy outcome by atopic asthma status
(atopic asthma, non-atopic asthma) and baseline use ofITT population 









MEDI-528 30 mg (n = 81)
Allocated to placebo
(n = 82)
AAllocated to MEDI-528 30 mg
(n = 82)
Lost to follow-up (n = 5)
Withdrawal of consent (n = 9)
Other (n = 4)
Lost to follow-up (n = 2)
Withdrawal of consent (n = 7)





Figure 2 Subject disposition.ICS (medium dose, high dose). A subgroup analysis was
conducted on the primary efficacy outcome by peripheral
blood eosinophil count < 0.3 × 103/μL or ≥ 0.3 × 103/μL.
Weighted asthma exacerbation rate and the 95% confi-
dence interval (CI) were calculated as the total number
of exacerbations/total duration of person-year follow-
up. The weighted asthma exacerbation rate at week 25
was analyzed using a pair-wise Poisson regression. Change
from baseline in pre-bronchodilator FEV1 at week 25
was compared between placebo and MEDI-528 using
a pair-wise t-test. The proportion of subjects with an
improvement in overall AQLQ(S) score of ≥ 0.5 at weeks
12 and 25 was compared between placebo and MEDI-528
using Fisher’s exact test. Safety variables were analyzed
descriptively based on the safety population.
Results
Subjects
Of the 329 randomized subjects, 327 received either
placebo or MEDI-528 and were included in the ITT
and safety populations. Overall, 64/82 (78.0%) of the
placebo-treated and 207/245 (84.5%) of the MEDI-528
treated subjects completed the study. The most common
reason for discontinuation was withdrawal of consent
(Figure 2).
Demographic characteristics were generally balanced
between the groups (Table 1). The study population
was predominantly female (69%) with a mean age of
43.0 years (range 18–65). Most subjects (84.4%) had
atopic asthma and 50.3% had evidence of a peripheral
blood eosinophilia (eosinophil count ≥ 0.3 × 103/μL).
Mean baseline ACQ-6 scores (2.8 for both placebo and
combined MEDI-528 groups) indicated uncontrolledITT population 











MEDI-528 100 mg (n = 83)
Allocated to MEDI-528 300 mg
(n = 82)
llocated to MEDI-528 100 mg
(n = 83)
Lost to follow-up (n = 1)
Withdrawal of consent (n = 5)
Other (n = 5)
Lost to follow-up (n = 4)
Withdrawal of consent (n = 3)









valueaPlacebo 30 mg 100 mg 300 mg Combined
(n = 82) (n = 81) (n = 83) (n = 81) (n = 245)
Age, years, mean (SD) 43.6 (11.6) 41.8 (11.1) 45.1 (11.6) 41.5 (12.3) 42.8 (11.7) 0.16
Male, n (%) 29 (35.4) 26 (32.1) 21 (25.3) 26 (32.1) 73 (29.8) 0.56
Race, n (%) 0.62
White 42 (51.2) 34 (42.0) 33 (39.8) 40 (49.4) 107 (43.7)
Asian 18 (22.0) 17 (21.0) 25 (30.1) 18 (22.2) 60 (24.5)
American Indian or Alaskan Native 5 (6.1) 8 (9.9) 8 (9.6) 4 (4.9) 20 (8.2)
Black or African American 2 (2.4) 3 (3.7) 4 (4.8) 5 (6.2) 12 (4.9)
Mixed race 1 (1.2) 0 (0.0) 0 (0.0) 2 (2.5) 2 (0.8)
Other 14 (17.1) 19 (23.5) 13 (15.7) 12 (14.8) 44 (18.0)
BMI, kg/m2, mean (SD) 27.6 (4.3) 27.1 (4.4) 26.9 (4.3) 27.2 (4.4) 27.1 (4.3) 0.79
FEV1 (L) 2.21 (0.74) 2.22 (0.71) 2.05 (0.62) 2.27 (0.66)
b 2.18 (0.67)c 0.19
FEV1, % predicted 70.7 (15.9) 71.8 (17.6) 70.6 (16.6) 72.2 (15.9)
b 71.5 (16.7)c 0.90
FVC, % predicted 83.9 (14.6) 86.1 (16.7) 84.8 (14.3) 84.7 (14.8) 85.2 (15.2) 0.83
FEV1/FVC 68.0 (10.4) 67.6 (10.8) 67.0 (11.3) 69.4 (10.8)
b 68.0 (11.0)c 0.57
FEV1 reversibility, %, mean (SD) 25.2 (13.8)
b 23.9 (10.2)d 25.6 (15.3)d 21.8 (11.1)e 23.8 (12.5)f 0.25
Atopic asthma, n (%) 70 (85.4) 69 (85.2) 69 (83.1) 68 (84.0) 206 (84.1) 0.98
Number of exacerbations requiring oral steroids in past year, n (%)g 0.33
0 2 (2.4) 5 (6.2) 1 (1.2) 4 (4.9) 10 (4.1)
1 45 (54.9) 47 (58.0) 42 (51.2) 39 (48.1) 128 (52.5)
2 16 (19.5) 12 (14.8) 16 (19.5) 12 (14.8) 40 (16.4)
3 5 (6.1) 5 (6.2) 10 (12.2) 15 (18.5) 30 (12.3)
4+ 14 (17.1) 12 (14.8) 13 (15.7) 11 (13.6) 36 (14.7)
ICS use, n (%) 0.81
Medium dose 43 (52.4) 38 (46.9) 38 (45.8) 41 (50.6) 117 (47.8)
High dose 39 (47.6) 43 (53.1) 45 (54.2) 40 (49.4) 128 (52.2)
Rescue medication use, puffs per day, mean (SD) 4.3 (4.0) 4.9 (5.6) 4.5 (4.5) 5.9 (7.3) 5.1 (5.9) 0.25
Mean ACQ-6 score, mean (SD) 2.8 (0.7) 2.7 (0.9) 2.8 (0.7) 2.9 (0.9) 2.8 (0.8) 0.62
Overall AQLQ(S) score, mean (SD) 3.6 (0.8)d 3.8 (1.1)h 3.8 (0.9)i 3.8 (0.9)h 3.8 (0.9)j 0.60
Eosinophil count ≥ 0.3 × 10 3/μL, n (%) 44 (53.7) 38 (47.5)b 43 (51.8) 39 (48.1) 120 (49.2)c 0.84
Eosinophil count (103/μL) 0.47
Mean 0.40 0.34b 0.40 0.35 0.36c
Median 0.31 0.28b 0.37 0.29 0.29c
Basophil count (103/μL) 0.05
Mean 0.03 0.03b 0.03 0.03 0.03c
Median 0.03 0.03b 0.02 0.03 0.02c
Abbreviations: ACQ-6 Asthma Control Questionnaire, AQLQ Asthma Quality of Life Questionnaire, BMI Body mass index, FEV1 Forced expiratory volume in 1 second,
FVC Forced vital capacity, ICS Inhaled corticosteroids, ITT Intent-to-treat.
aP value for differences among groups (placebo and MEDI-528 groups) by analysis of variance for continuous variables and the chi-square test for
categorical variables.
bn = 80; cn = 244; dn=79; en=78; fn=236; gOne value is missing in the MEDI-528 100 mg group; hn = 76; in = 81; jn = 233.
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528, n = 3) had a mean ACQ-6 score < 1.5 suggesting that
their asthma was more controlled. Almost all subjects had
experienced ≥ 1 exacerbation requiring oral steroids in
the past year (placebo 80/82, 97.6%; MEDI-528 234/244,
95.9%). At baseline, an average of 2.06 exacerbations/subject required oral steroids during the previous year.
Subjects in the placebo group appeared to have less severe
asthma than those in the MEDI-528 groups, according
to the proportion taking high-dose ICS (47.6% vs 52.2%)
and rescue medication use (mean number of puffs per day
4.3 vs 5.1), although there were no statistically significant
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The primary outcome measure analyzed using an analysis
of covariance model, change from baseline to week 13
in mean ACQ scores, was not significantly different be-
tween the placebo and the individual MEDI-528 groups
(p = 0.80). Improvements in mean ACQ-6 score occurred
in all groups at weeks 13 and 25, with little difference
between placebo and the individual MEDI-528 treatment
groups (Figure 3). Clinically relevant improvements of ≥
0.5 in mean ACQ-6 score occurred in similar proportions
of placebo and combined MEDI-528 subjects at week
13 (64/82 [78.0%] vs 184/245 [75.1%], p = 0.66) and week
25 (59/82 [72.0%] vs 194/245 [79.2%], p = 0.22). In the in-
dividual MEDI-528 groups, a clinically relevant improve-
ment was seen in the following proportions of subjects at
week 13: 30 mg, 54/81 (66.7%); 100 mg, 66/83 (79.5%);
and 300 mg, 64/81 (79.0%); and at week 25: 30 mg, 61/81
(75.3%); 100 mg, 67/83 (80.7%); and 300 mg, 66/81
(81.5%).
Differences between placebo and the combined MEDI-
528 groups were not significantly different when analyzed
by atopic or non-atopic asthma, baseline medium- or
high-dose ICS use, or peripheral blood eosinophil count <
0.3 or ≥ 0.3 × 103/μL (Table 2). In addition, there was
no difference between the steroid-stable and steroid
reduction phases with regard to the effect of ICS and




















Figure 3 Mean (SE) change from baseline in mean ACQ-6 score at we
Control Questionnaire-6; ITT, Intent-to-treat; SE, Standard error.Asthma exacerbation rate
At week 25, the weighted asthma exacerbation rate (ex-
acerbations/subject/year, 95% CI) for the placebo group
was 0.58 (0.36 − 0.88) compared with 0.49 (0.37 − 0.64)
in the combined MEDI-528 groups (p = 0.52). Results
were similar for the individual MEDI-528 dose groups
(Figure 4); weighted asthma exacerbation rates (95% CI)
at week 25 were 0.64 (0.40 − 0.96) (p = 0.76) for 30 mg,
0.28 (0.14 − 0.50) (p = 0.05) for 100 mg, and 0.58 (0.36 −
0.88) (p = 1.00) for 300 mg.Pre-bronchodilator FEV1
Mean increase from baseline in pre-bronchodilator FEV1
was similar between the placebo and MEDI-528 groups
at weeks 13 and 25 (Figure 5). The FEV1 % predicted
mean (SD) change from baseline at week 25 for placebo
vs the combined MEDI-528 groups was 1.44% (11.08) vs
1.12% (9.81) (p = 0.82); mean (SD) change in FEV1 abso-
lute values were 0.04 L (0.37) vs 0.03 L (0.30) (p = 0.82). In
the individual MEDI-528 dose groups, mean (SD) change
from baseline at week 25 was −0.01 L (0.32) (p = 0.41)
for 30 mg, 0.06 L (0.30) (p = 0.85) for 100 mg, and 0.05 L
(0.29) (p = 0.97) for 300 mg.Health-related quality of life
A clinically relevant improvement of ≥ 0.5 in overall AQ
LQ(S) score was seen in similar proportions of placebo
and MEDI-528 subjects at week 12 (53/69, 76.8% vs 144/
207, 69.6%; p = 0.21) and week 25 (50/62, 80.6% vs 136/







eks 13 and 25 (ITT population). Abbreviations: ACQ-6, Asthma
Table 2 ACQ score change from baseline to week 13 (ITT population)
Variable
Placebo Combined MEDI-528 P
Valuebn Mean (SD) n Mean (SD)
All subjectsa 82 −1.23 (0.95) 245 −1.22 (1.07) 0.86
Asthma typea
Atopic 70 −1.28 (0.97) 206 −1.19 (1.04) 0.55
Non-atopic 12 −0.94 (0.82) 39 −1.42 (1.18) 0.41
ICS usea
Medium dose 43 −1.21 (0.97) 117 −1.17 (1.02) 0.55
High dose 39 −1.26 (0.94) 128 −1.28 (1.11) 0.77
Eosinophil counta
≥ 0.3 × 103/μL 44 −1.39 (0.95) 120 −1.17 (1.01) 0.14
< 0.3 × 103/μL 38 −1.04 (0.92) 124 −1.26 (1.09) 0.22
All subjects without imputation 67 −1.30 (0.94) 208 −1.28 (1.10) 0.75
Abbreviations: ACQ Asthma Control Questionnaire, ICS Inhaled corticosteroid.
aMissing mean ACQ score at Week 13 was imputed using the last observation carried forward method.
bP-values are calculated using an analysis of covariance with treatment and baseline value as covariates.
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The proportion of subjects who reported at least one
AE was similar between the placebo (68/82, 82.9%) and
MEDI-528 (30 mg: 62/81, 76.5%; 100 mg: 68/83, 81.9%;
300 mg: 69/81, 85.2%) groups. The most frequent AEs
in the combined MEDI-528 groups were asthma, upper
respiratory tract infection, and headache (Table 3). Most
AEs were mild or moderate in severity. One subject in
the MEDI-528 100 mg group had a mild hypersensitivity
reaction on the day of dosing that was considered possibly





















Number of exacerbations 22 23
Figure 4 Weighted rate of asthma exacerbation (95% CI) at week 25SAEs were reported by 4 (4.9%) and 15 (6.1%) subjects
in the placebo and combined MEDI-528 groups, respect-
ively (Table 4). Two SAEs (pneumonia and asthma) in one
subject who received 30 mg MEDI-528 were considered
to be possibly related to study medication. Six subjects
discontinued the study due to AEs: one placebo (rash);
two 30 mg MEDI-528 (ischemic stroke, headache); one
100 mg MEDI-528 (musculoskeletal pain and pain in
extremity); and two 300 mg MEDI-528 (headache, bladder
transitional cell carcinoma). Three of the AEs that resulted
in discontinuation were considered likely to be related 30 mg MEDI-528 100 mg MEDI-528 300 mg
11 22





























Figure 5 Mean (SE) change from baseline in pre-bronchodilator FEV1 at week s 13 and 25 (ITT population). Abbreviations: FEV1, Forced
expiratory volume in 1 second; ITT, Intent-to-treat; SE, Standard error.
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pain in extremity; 300 mg, headache).
No clinically relevant changes occurred in clinical labora-
tory values, vital signs, or ECGs.
ADAs occurred in 4/82 subjects (4.9%) in the placebo
group and 22/245 subjects (9.0%) in the MEDI-528 groups
(30 mg: 15/81, 18.5%; 100 mg: 4/83, 4.8%; 300 mg: 3/81,
3.7%). ADAs were detected prior to day 0 in 1 subject in
the placebo group and 14 subjects in the MEDI-528 group.
Discussion
This is the largest double-blind, placebo-controlled, dose-
ranging study performed to date to determine whether
an anti-IL-9 monoclonal antibody has any clinical bene-
fits in subjects with poorly controlled, moderate-to-severe
asthma. The results indicate that adding MEDI-528 to
existing controller medications was not associated with
any major safety concerns, but failed to achieve a clinically
important effect on mean ACQ-6 scores at 13 weeks or
on asthma exacerbation rates, lung function, or asthma-
related quality of life at the pre-specified time points.
However, this study was powered to detect a change in
the primary study endpoint of mean ACQ-6 score from
baseline to week 13, thus statistical results for the second-
ary endpoints must be viewed in this context.
Data from preclinical studies provide strong evidence
that an IL-9 mast cell axis regulates airway inflam-
mation, mucus production, airway hyperresponsiveness,and subepithelial fibrosis, with increased IL-9 expression
in the airways in humans with asthma [5]. For example,
both Th9 and Th17 are involved in asthma pathogenesis
and produce IL-9 [17]. Kim et al. demonstrated in Balb/c
mice that cellular infiltration related to chronic airway
inflammation and remodeling can be reduced by an anti-
IL-9 antibody. In addition, the number of Th9 cells, Th17
cells, mast cells, eosinophils, and neutrophils in the airway
were reduced; the synthesis and secretion of cytokines
was inhibited; and IgE synthesis in B cells was reduced
[18]. These reported observations support our hypothesis
that targeting IL-9 via an anti-IL-9 mAb would be an
effective treatment for patients with poorly controlled
asthma. Despite convincing in vitro and animal model
data, there have been very few studies in humans examin-
ing IL-9 involvement in asthma.
In a previous small study in subjects with mild asthma,
fewer subjects experienced ≥ 1 asthma exacerbation in
the combined MEDI-528 group (1/27) compared with the
placebo group (2/9; p = 0.15). The subject in the MEDI-
528 group who experienced an exacerbation received
the lowest dose (0.3 mg/kg), which indicated that it was
not due to a dose effect. These results suggested a poten-
tial improvement in asthma exacerbation rates in subjects
with mild asthma [11]. However, in the current study,
no significant differences in the asthma exacerbation
rate occurred between placebo and MEDI-528 in adults
with uncontrolled moderate-to-severe persistent asthma.
Table 3 Adverse events that occurred in ≥ 2% of the combined MEDI-528 group (safety population)
Adverse event, n (%) of subjects
MEDI-528
Placebo 30 mg 100 mg 300 mg Combined
(n = 82) (n = 81) (n = 83) (n = 81) (n = 245)
Asthma 25 (30.5) 30 (37.0) 21 (25.3) 31 (38.3) 82 (33.5)
Upper respiratory tract infection 12 (14.6) 6 (7.4) 16 (19.3) 20 (24.7) 42 (17.1)
Headache 8 (9.8) 13 (16.0) 5 (6.0) 6 (7.4) 24 (9.8)
Nasopharyngitis 12 (14.6) 11 (13.6) 5 (6.0) 7 (8.6) 23 (9.4)
Sinusitis 4 (4.9) 10 (12.3) 4 (4.8) 6 (7.4) 20 (8.2)
Influenza 6 (7.3) 10 (12.3) 5 (6.0) 2 (2.5) 17 (6.9)
Urinary tract infection 6 (7.3) 7 (8.6) 7 (8.4) 2 (2.5) 16 (6.5)
Pharyngitis 2 (2.4) 4 (4.9) 8 (9.6) 4 (4.9) 16 (6.5)
Bronchitis 8 (9.8) 4 (4.9) 2 (2.4) 5 (6.2) 11 (4.5)
Injection site erythema 2 (2.4) 1 (1.2) 4 (4.8) 5 (6.2) 10 (4.1)
Allergic rhinitis 7 (8.5) 5 (6.2) 1 (1.2) 3 (3.7) 9 (3.7)
Gastroenteritis 3 (3.7) 2 (2.5) 5 (6.0) 2 (2.5) 9 (3.7)
Diarrhea 2 (2.4) 3 (3.7) 3 (3.6) 3 (3.7) 9 (3.7)
Rhinitis 5 (6.1) 3 (3.7) 3 (3.6) 2 (2.5) 8 (3.3)
Back pain 2 (2.4) 3 (3.7) 3 (3.6) 2 (2.5) 8 (3.3)
Pneumonia 0 (0.0) 5 (6.2) 0 (0.0) 3 (3.7) 8 (3.3)
Dizziness 5 (6.1) 2 (2.5) 5 (6.0) 0 (0.0) 7 (2.9)
Injection site pain 5 (6.1) 1 (1.2) 4 (4.8) 2 (2.5) 7 (2.9)
Rash 3 (3.7) 2 (2.5) 1 (1.2) 4 (4.9) 7 (2.9)
Acute sinusitis 2 (2.4) 3 (3.7) 2 (2.4) 2 (2.5) 7 (2.9)
Hypertension 2 (2.4) 4 (4.9) 3 (3.6) 0 (0.0) 7 (2.9)
Pain in extremity 2 (2.4) 1 (1.2) 3 (3.6) 3 (3.7) 7 (2.9)
Cough 0 (0.0) 2 (2.5) 2 (2.4) 3 (3.7) 7 (2.9)
Oropharyngeal pain 0 (0.0) 2 (2.5) 3 (3.6) 2 (2.5) 7 (2.9)
Pyrexia 0 (0.0) 0 (0.0) 4 (4.8) 3 (3.7) 7 (2.9)
Migraine 1 (1.2) 4 (4.9) 1 (1.2) 1 (1.2) 6 (2.4)
Pruritus 1 (1.2) 1 (1.2) 2 (2.4) 3 (3.7) 6 (2.4)
Toothache 1 (1.2) 2 (2.5) 4 (4.8) 0 (0.0) 6 (2.4)
Nasal congestion 0 (0.0) 2 (2.5) 3 (3.6) 1 (1.2) 6 (2.4)
Pharyngotonsillitis 0 (0.0) 5 (6.2) 0 (0.0) 1 (1.2) 6 (2.4)
Bacterial upper respiratory tract infection 0 (0.0) 2 (2.5) 2 (2.4) 2 (2.5) 6 (2.4)
Asthenia 2 (2.4) 3 (3.7) 1 (1.2) 1 (1.2) 5 (2.0)
Malaise 1 (1.2) 0 (0.0) 3 (3.6) 2 (2.5) 5 (2.0)
Dyspepsia 0 (0.0) 3 (3.7) 1 (1.2) 1 (1.2) 5 (2.0)
Musculoskeletal pain 0 (0.0) 1 (1.2) 4 (4.8) 0 (0.0) 5 (2.0)
Bacterial pharyngitis 0 (0.0) 2 (2.5) 1 (1.2) 2 (2.5) 5 (2.0)
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bronchodilator FEV1 was similar between the MEDI-
528 and placebo groups, which is consistent with the
earlier study where FEV1 was essentially unchanged and
short-acting beta agonist use was comparable among
groups [11]. Studies with other monoclonal antibodies,
including omalizumab [19] and mepolizumab [20], also
reported modest, if any, improvements in FEV1.Although the study did not meet its primary endpoint,
all groups, including placebo, demonstrated improvements
in mean ACQ-6 score at 13 weeks. The placebo response
has been well described in asthma studies and various
explanations have been proposed. For example, Wise et al.
reported that the placebo effect on asthma symptoms
could be augmented by an optimistic message from the
physician that enhanced the subject’s expectation of
Table 4 Serious adverse events by treatment group (safety population)
Serious adverse event,
n (%) of subjects
MEDI-528
Placebo 30 mg 100 mg 300 mg Combined
(n = 82) (n = 81) (n = 83) (n = 81) (n = 245)
Asthma 0 (0.0) 6 (7.4) 1 (1.2) 2 (2.5) 9 (3.7)
Pneumonia 0 (0.0) 3 (3.7) 0 (0.0) 0 (0.0) 3 (1.2)
Food allergy 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.4)
Bronchitis 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.4)
Lobar pneumonia 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) 1 (0.4)
Limb traumatic amputation 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.4)
Thoracic vertebral fracture 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) 1 (0.4)
Muscle spasms 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) 1 (0.4)
Uterine leiomyoma 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) 1 (0.4)
Complicated migraine 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.4)
Ischemic stroke 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) 1 (0.4)
Vaginal hemorrhage 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) 1 (0.4)
Pancreatitis 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Cholelithiasis 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hydrocholecystis 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Appendicitis 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nephrolithiasis 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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response was observed in two pivotal studies of
omalizumab and was explained by improved com-
pliance with ICS treatment and/or intensive medical
input [22].
It is becoming increasingly apparent that asthma is a
heterogeneous disease, and that identification of poten-
tial subgroups or individual subject characteristics is likely
to be key in delivering optimal response with therapeutics
such as MEDI-528 that target specific immunological
mechanisms. Subgroup analyses of the mean ACQ-6
score results provided no evidence that MEDI-528 may
be effective in subjects with atopic asthma, peripheral
blood eosinophilia, or in those taking moderate or high
doses of ICS at entry to the study. Interpretation of these
results should take into account the small numbers of
subjects in some subgroups.
The heterogeneous nature of asthma makes it difficult
for a targeted therapy with monoclonal antibodies such
as MEDI-528 to show significant beneficial effects in a
non-selected asthma population. Identification of bio-
logical markers may be of great help in determining
more accurate asthma diagnosis and severity, predicting
treatment response, or monitoring of disease control.
Corren et al. showed that lebrikizumab increased FEV1
and reduced exacerbations in the high Th2 subgroup vs
placebo [23]. Unfortunately, a pharmacodynamic marker
for the IL-9 pathway has not been identified and IL-9 levels
couldn’t be measured in blood or sputum in this study.
Furthermore, subgroup analyses of the primary endpointin pre-specified subpopulations, stratified by atopic status
or medium- vs high-dose ICS at screening, and other
pre-specified subpopulations based on FEV1, ACQ score,
reversibility, and blood eosinophilia at randomization
did not identify a subpopulation with improved efficacy
over placebo.
Overall, the safety profile of MEDI-528 was similar to
earlier clinical studies [11,12] and no new safety concerns
were identified. ADAs were detected in the placebo and
all three MEDI-528 treatment groups. None of these
events were considered to be serious, but it is unclear
why ADAs were detected in the placebo group or in some
subjects prior to administration of MEDI-528. Our ADA
assays may nonspecifically detect cross-reacting antigen or
other epitopes; however, it is not uncommon for subjects
to develop antibodies against a biologic agent [24].
Conclusions
This study was designed to further evaluate the clinical
effects of MEDI-528, an anti-IL-9 antibody, in light of the
inconclusive results obtained in previous small studies.
In this large study, we clearly demonstrated that adding
MEDI-528 to existing controller medications was not
associated with an improvement in ACQ-6 score, asthma
exacerbation rate, FEV1, health-related quality of life, or
any major safety concerns.
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